Furthermore, investigations have revealed the potential synergy between TIC10 and EMs such as EZH2 inhibitors and HDAC inhibitors across multiple cancer types, substantiating the rationale for such combination strategies [45]. The gene discussed is EZH2; the disease is cancer.